Alx Oncology Holdings Cash Flow Conversion Efficiency
Alx Oncology Holdings cash flow conversion efficiency. Based on the latest financial reports, Alx Oncology Holdings (ALXO) has a cash flow conversion efficiency ratio of -0.118x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.06 Million) by net assets ($136.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Alx Oncology Holdings (2018–2025)
Cash flow conversion efficiency of Alx Oncology Holdings from 2018 to 2025. This chart illustrates how Alx Oncology Holdings 's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ALXO stock price and chart for real-time trading data and today's change.
Alx Oncology Holdings Cash Flow Conversion Ratio Explained
Alx Oncology Holdings cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Alx Oncology Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alx Oncology Holdings ranked by their cash flow conversion efficiency. Also see Alx Oncology Holdings market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asian Sea Corporation Public Company Limited
BK:ASIAN
|
0.060x |
|
Spandana Sphoorty Financial Limited
NSE:SPANDANA
|
0.624x |
|
Thanulux Public Company Limited
BK:TNL
|
-0.039x |
|
Falcon Oil & Gas Ltd
F:FAC
|
-0.012x |
|
King Core Electronics Inc
TW:6155
|
0.045x |
|
Nova Minerals Ltd
AU:NVA
|
-0.028x |
|
Rockfields Property Indonesia Pt
JK:ROCK
|
0.025x |
|
Sierra Metals Inc.
TO:SMT
|
0.249x |
Annual Cash Flow Conversion Efficiency for Alx Oncology Holdings (2018–2025)
The table below shows the annual cash flow conversion efficiency of Alx Oncology Holdings from 2018 to 2025. Review Alx Oncology Holdings (ALXO) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $25.98 Million | $-84.14 Million | -3.239x | -201.83% |
| 2024-12-31 | $113.62 Million | $-121.91 Million | -1.073x | -56.15% |
| 2023-12-31 | $189.71 Million | $-130.36 Million | -0.687x | -102.91% |
| 2022-12-31 | $263.46 Million | $-89.22 Million | -0.339x | -80.54% |
| 2021-12-31 | $363.05 Million | $-68.10 Million | -0.188x | -110.58% |
| 2020-12-31 | $429.85 Million | $-38.29 Million | -0.089x | -100.17% |
| 2019-12-31 | $-276.00K | $-14.25 Million | 51.627x | +3683.35% |
| 2018-12-31 | $9.15 Million | $-13.19 Million | -1.441x | -- |
About Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collabora… Read more